Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib

Pemigatinib is a fibroblast growth factor receptor inhibitor (FGFRi) approved for the treatment of patients with previously treated biliary tract cancer with FGFR2 fusion. Although infrequent, ocular toxicity manifested as serous retinal detachment (SRD) has been observed and is regarded as a seriou...

Descripción completa

Detalles Bibliográficos
Autores principales: Yukutake, Masanobu, Sekito, Tsuyoshi, Yamakita, Ichiko, Itakura, Hideki, Kabu, Koki, Nagata, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183291/
https://www.ncbi.nlm.nih.gov/pubmed/35945011
http://dx.doi.org/10.2169/internalmedicine.0150-22
_version_ 1785041925070389248
author Yukutake, Masanobu
Sekito, Tsuyoshi
Yamakita, Ichiko
Itakura, Hideki
Kabu, Koki
Nagata, Shinji
author_facet Yukutake, Masanobu
Sekito, Tsuyoshi
Yamakita, Ichiko
Itakura, Hideki
Kabu, Koki
Nagata, Shinji
author_sort Yukutake, Masanobu
collection PubMed
description Pemigatinib is a fibroblast growth factor receptor inhibitor (FGFRi) approved for the treatment of patients with previously treated biliary tract cancer with FGFR2 fusion. Although infrequent, ocular toxicity manifested as serous retinal detachment (SRD) has been observed and is regarded as a serious side effect. We herein report the case of a 54-year-old woman with unresectable cholangiocarcinoma-initiated pemigatinib after failure of gemcitabine plus S-1 (GS). Although the patient experienced repeated SRD after pemigatinib, dose interruption and dose reduction of pemigatinib from 13.5 mg to 9 mg, and from 9 mg to 4.5 mg led to complete recovery of SRD, and continued tumor shrinkage.
format Online
Article
Text
id pubmed-10183291
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-101832912023-05-15 Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib Yukutake, Masanobu Sekito, Tsuyoshi Yamakita, Ichiko Itakura, Hideki Kabu, Koki Nagata, Shinji Intern Med Case Report Pemigatinib is a fibroblast growth factor receptor inhibitor (FGFRi) approved for the treatment of patients with previously treated biliary tract cancer with FGFR2 fusion. Although infrequent, ocular toxicity manifested as serous retinal detachment (SRD) has been observed and is regarded as a serious side effect. We herein report the case of a 54-year-old woman with unresectable cholangiocarcinoma-initiated pemigatinib after failure of gemcitabine plus S-1 (GS). Although the patient experienced repeated SRD after pemigatinib, dose interruption and dose reduction of pemigatinib from 13.5 mg to 9 mg, and from 9 mg to 4.5 mg led to complete recovery of SRD, and continued tumor shrinkage. The Japanese Society of Internal Medicine 2022-08-10 2023-04-15 /pmc/articles/PMC10183291/ /pubmed/35945011 http://dx.doi.org/10.2169/internalmedicine.0150-22 Text en Copyright © 2023 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Yukutake, Masanobu
Sekito, Tsuyoshi
Yamakita, Ichiko
Itakura, Hideki
Kabu, Koki
Nagata, Shinji
Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib
title Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib
title_full Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib
title_fullStr Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib
title_full_unstemmed Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib
title_short Favorable Management of Repeated Serous Retinal Detachment with Continued Tumor Response in a Patient with Intrahepatic Cholangiocarcinoma during Treatment with Pemigatinib
title_sort favorable management of repeated serous retinal detachment with continued tumor response in a patient with intrahepatic cholangiocarcinoma during treatment with pemigatinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183291/
https://www.ncbi.nlm.nih.gov/pubmed/35945011
http://dx.doi.org/10.2169/internalmedicine.0150-22
work_keys_str_mv AT yukutakemasanobu favorablemanagementofrepeatedserousretinaldetachmentwithcontinuedtumorresponseinapatientwithintrahepaticcholangiocarcinomaduringtreatmentwithpemigatinib
AT sekitotsuyoshi favorablemanagementofrepeatedserousretinaldetachmentwithcontinuedtumorresponseinapatientwithintrahepaticcholangiocarcinomaduringtreatmentwithpemigatinib
AT yamakitaichiko favorablemanagementofrepeatedserousretinaldetachmentwithcontinuedtumorresponseinapatientwithintrahepaticcholangiocarcinomaduringtreatmentwithpemigatinib
AT itakurahideki favorablemanagementofrepeatedserousretinaldetachmentwithcontinuedtumorresponseinapatientwithintrahepaticcholangiocarcinomaduringtreatmentwithpemigatinib
AT kabukoki favorablemanagementofrepeatedserousretinaldetachmentwithcontinuedtumorresponseinapatientwithintrahepaticcholangiocarcinomaduringtreatmentwithpemigatinib
AT nagatashinji favorablemanagementofrepeatedserousretinaldetachmentwithcontinuedtumorresponseinapatientwithintrahepaticcholangiocarcinomaduringtreatmentwithpemigatinib

Ejemplares similares